Article
Pharmacokinetic analysis of 6-O-[18F]FEE for PET imaging of EGFR mutation.
Bioorganic & medicinal chemistry letters - 1 Apr 2023
Shi Dazhi, Dong Ye, Zhou Wenlan, Bai Lu, Huang Jiawen, Han Yanjiang, Sun Penghui, Huang Yanchao, Huang Yong, Chen Li, Cao Min, Wu Hubing, Huang Shun
Abstract excerpt
6-O-[18F]Fluoroethylerlotinib (6-O-[18F]FEE), with a suitable half-life for commercial distribution, may be a good replacement for [11C]erlotinib to identify epidermal growth factor receptor (EGFR) positive tumors with activating mutations to tyrosine kinase inhibitors therapy. In this study, we explored the fully automated synthesis of 6-O-[18F]FEE and investigated its pharmacokinetics in tumor-bearing mice....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.